BNP Paribas Discount Zert QIA 27..../ DE000PE9F123 /
| 2024-06-20 9:40:11 PM | Chg.0.000 | Bid2024-06-20 | Ask- | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 29.840EUR | 0.00% | - Bid Size: - |
- Ask Size: - |
QIAGEN NV | - EUR | 2024-06-27 | Call |
GlobeNewswire
06-13
QIAGEN’s software QCI Interpret accelerates clinical reporting turnaround time for high throughput N...
GlobeNewswire
06-12
QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to su...
GlobeNewswire
06-11
QIAGEN launches new QIAcuity digital PCR assays for microbial applications, enhancing infectious dis...
GlobeNewswire
06-06
QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition per...
GlobeNewswire
06-05
QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of it...
GlobeNewswire
06-03
QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improv...
GlobeNewswire
05-30
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global...
GlobeNewswire
05-30
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global...
GlobeNewswire
05-29
QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision ...
GlobeNewswire
05-14
QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical devic...
GlobeNewswire
05-13
QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accura...
GlobeNewswire
05-07
QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics
GlobeNewswire
05-07
Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq
GlobeNewswire
05-07
Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq
GlobeNewswire
05-02
QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inher...
GlobeNewswire
04-29
QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance
GlobeNewswire
04-25
deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ...
GlobeNewswire
04-24
QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and comba...
GlobeNewswire
04-18
deepull appoints Kimberle Chapin, MD, as Chief Medical Officer and Wade Stevenson as Chief Marketing...
GlobeNewswire
04-03
QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Ann...
